<DOC>
	<DOCNO>NCT00869726</DOCNO>
	<brief_summary>The purpose study determine whether MBP8298 effective safe treatment secondary progressive multiple sclerosis . Dirucotide generic name MBP8298 .</brief_summary>
	<brief_title>A Study Patients With Secondary Progressive Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<criteria>Documented history SPMS Absence relapse 3mos prior baseline EDSS 3.5 6.5 Pyramidal Cerebellar FSS great equal 3 A cohort 100 HLA DR2/4 negative patient require . Once enrollment cohort complete , patient require HLA DR2/4 positive . Informed consent Subject reliability compliance Diagnosis Primary Progressive MS Subjects previously receive MBP8298 Recent history malignancy , exclusion basal cell carcinoma . Steroid therapy within 30 day prior first study specific procedure treatment know used putative experimental MS treatment Therapy betainterferon , glatiramer acetate within 3 mo mitoxantrone , cyclophosphamide , methotrexate , azathioprine , immunomodulating immunosuppressive drug include recombinant nonrecombinant cytokine plasma exchange within 6 mo prior performance first studyspecific test , exception corticosteroid ACTH relapse treatment . Initiation discontinuation therapy 4AP 3,4DAP time study period . History anaphylactic/anaphlactoid reaction glatiramer acetate Abnormal lab value Screening Visit deem Investigator clinically significant Known allergy GadoliniumDTPA Treatment time Cladribine , total lymphoid irradiation , monoclonal antibody treatment Treatment time wtih alter peptide ligand Any condition could interfere performance study specific procedure e.g.MRI Previous randomization study Known positivity HIV , Hepatitis B , Hepatitis C Participation nonMS clinical trial within 30 day prior performance first study specific test investigational therapy past 6 mo . Females breast feeding , pregnant use medically approve method contraception regularly Known suspect current past alcohol drug abuse ( within last year ) Any medical , psychiatric condition could result subject able give fully inform consent , comply protocol requirement Any condition , investigator 's opinion , make subject unsuitable participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>